Trial · NCT07909590
A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning
NCT07909590, Not yet recruiting, HALEON
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning. Trials, record NCT07909590. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909590
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning
- NCT number
- NCT07909590
- Status
- Not yet recruiting
- Enrollment
- 2,100 participants, estimated
- Lead sponsor
- HALEON
- Conditions
- Pain
- Interventions
- Paracetamol
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Intensity Before Using Panadol/Dolex | Within the past 1 month from time of participation | Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome. |
| Primary | Perceived Relief From Panadol/Dolex Use | Within the past 1 month from time of participation | Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex. |
| Primary | QoL Assessment After Using Panadol/Dolex Post Headache Episode | Within the past 1 month from time of participation | Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life. |
| Secondary | Frequency of Panadol/Dolex Use | Within the past 1 month from time of participation | Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day. |
| Secondary | Timepoint of Panadol/Dolex Use | Within the past 1 month from time of participation | Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options. |
| Secondary | Product Satisfaction | Within the past 1 month from time of participation | Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied. |
| Secondary | Headache Management Behaviors | Within the past 1 month from time of participation | Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided. |
| Secondary | User Attitudes Towards Panadol/Dolex: Trust in The Product | Within the past 1 month from time of participation | Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options. |
| Secondary | User Attitudes Towards Panadol/Dolex: Value For Money | Within the past 1 month from time of participation | Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money. |
| Secondary | User Attitudes Towards Panadol/Dolex: Intention to Use Again | Within the past 1 month from time of participation | Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909590
GET https://conductscience.org/api/trials/v1/NCT07909590/registered